



PATENT
ATTORNEY DOCKET NO.: 056291-5011

#7
2/8/03
C. Style

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:

THOMAS et al.

Appln. No.: 10/069,019

Filed: February 21, 2002

FOR: IMIDAZO[1,2-A]PYRIDINE AND
PYRAZOLO[2,3-A]PYRIDINE
DERIVATIVES

)
)
)
)
) Group Art Unit: 1624
)
) Examiner: Balasubramanian, V.
)
)
)

Commissioner of Patents
Washington, D.C. 20231

Date: January 14, 2003

Sir:

INFORMATION DISCLOSURE STATEMENT

Citation of Related U.S. Patent Applications

The Examiner's attention is directed to the following related co-pending U.S. patent applications:

Examiner's Initials	Inventor	U.S. Serial No.	U.S. Filing Date	PCT Publication No.	PCT Publication Date
	Pease et al.	10/203,154	8/6/02	PCT/GB01/00824 WO 01/64655	Sept. 7, 2001
	Pease et al.	10/220,139	08/28/02	PCT/GB01/00782 WO 01/64654	Sept. 7, 2001
	Pease et al.	10/203,025	8/5/02	PCT/GB01/00829 WO 01/64656	Sept. 7, 2001
	Pease et al.	10/203,549	8/8/02	PCT/GB01/00794 WO 01/64653	Sept. 7, 2001
	Thomas et al.	10/239,790	09/25/2002	PCT/GB01/01264 WO 01/72717	Oct. 4, 2001
	Thomas et al.		01/07/03	PCT/GB01/03084 WO 01/04429	Jan. 17, 2002

A copy of the specification and claims for each application, in the form of the published PCT application from which such application was filed, has previously been provided.

PLEASE DO NOT PRINT the above information on the patent resulting from the subject application.

Consideration of each listed application is earnestly solicited since unpublished patent applications are contemplated as IDS material; see the exception in Rule 98(a)(2)(iii) and note the penultimate sentence of MPEP 609.

Further, in keeping with MPEP 609, Subsec. C(2), 2nd para., line 10 to end of the paragraph (especially note lines 18-25) PLEASE RETURN A COPY OF THIS LETTER with the Examiner's initials adjacent each above listing so that applicant will know that each listed application has been considered as required by PTO policy.

Citation of Documents

Attached is a Form PTO-1449 listing the enclosed documents.


This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.

Please charge the Rule 17(p) official fee required by Rule 97(c) to our Deposit Account No. 50-0310 under Order No. 056291-5011.

Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly solicited.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** -in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP



Date: January 14, 2003
Morgan Lewis & Bockius LLP
Customer No. **009629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:mk

By:

Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001